

【公報種別】特許法第17条の2の規定による補正の掲載

【部門区分】第1部門第1区分

【発行日】平成17年7月28日(2005.7.28)

【公開番号】特開2003-199581(P2003-199581A)

【公開日】平成15年7月15日(2003.7.15)

【出願番号】特願2002-34378(P2002-34378)

【国際特許分類第7版】

C 1 2 N 15/09

C 1 2 N 5/10

C 1 2 Q 1/02

C 1 2 Q 1/68

G 0 1 N 33/15

G 0 1 N 33/50

G 0 1 N 33/53

G 0 1 N 33/566

【F I】

C 1 2 N 15/00 Z N A A

C 1 2 Q 1/02

C 1 2 Q 1/68 A

G 0 1 N 33/15 Z

G 0 1 N 33/50 Z

G 0 1 N 33/53 M

G 0 1 N 33/566

C 1 2 N 5/00 B

【手続補正書】

【提出日】平成16年10月15日(2004.10.15)

【手続補正1】

【補正対象書類名】明細書

【補正対象項目名】0 0 4 0

【補正方法】変更

【補正の内容】

【0 0 4 0】

【配列表】

SEQUENCE LISTING

<110> Japan Science And Technology Corporation
Sakamoto, Aiji

<120> A Method for Evaluation or Identification for Bioactive Molecules
with the Use of Marker Genes.

<130> PC909155

<150> JP 2001-327576

<151> 2001-10-25

<160> 32

<170> PatentIn Ver. 2.1

<210> 1

<211> 900

<212> DNA

<213> Hamster sp.

<220>

<221> CDS

<222> (875)..(901)

<400> 1

tagcgctacc ggactcagat ctcgaggaag ctgtgtgacc ttggaggagg cactccacc 60

tccataaaact aaagcactca cttggatgga tcaccagaga cctgtctggc tctgaggctc 120

ggtgaccta acacattgtc tgctggcca aggaaagcgg tgccctgagcc agagttccag 180

tgtctaaact ctggtcattc ttcttcctcc ttaacttagga agctgcctcc tagctgctcc 240

aatccagctg ccataccagg gccatgcccgg actctgcctt gcccctctt gctgtggtaa 300

ctaggcccct tcccaccta gtgagatgtg ggactcaggc cagtagagta gggaggattc 360

tggaaacaga gccaggctag tgctggggc caggactcca aggggcagca tgccagggca 420

gggcaggggct ctgtctgcct aaggcatgg tggtcgttgt cagcttactc tgcaagtgagc 480

tgtggaatgt aagagatatt ttctgttcgc tttgagccac cccacccctt ggaactcaga 540

ccctgaacat gccatgccac aacaatgacg accacttcca attgtttcct ggctgggggg 600

ggagggggag cactgtttgg acaagggaaag ggggggagtc gagggggaaa tgcttttagt 660

gacaacagcc ctttctaaat ctggctaggg actgggtgca ggtgggggtg gggcacctt 720

ctgccccata tatacaaccc ctgaggccag gtctgactct gagcagtctc ctgctgttc 780

cttccttgct gccctcaggt aggagtggga gctggaggcc tcctctggta taagggctc 840

cagattcagg aagagggatc caccggtcgc cacc atg gtg agc aag ggc gag gag 895

Met Val Ser Lys Gly Glu Glu

1

5

ctg ttc

901

Leu Phe

<210> 2

<211> 9
<212> PRT
<213> Hamster sp.

<400> 2
Met Val Ser Lys Gly Glu Glu Leu Phe
1 5

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
prepro-endothelin-1 (ppET-1) , forward primer

<400> 3
ccaaggagct ccagaaacag 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
prepro-endothelin-1(ppET-1) , reverse primer

<400> 4
ttgaccgcaga tgatgtccag 20

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
ETA endothelin receptor (ETAR) , forward primer

<400> 5
tctgcgcgct aagtgttgac aggt 24

<210> 6

<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
ETA endothelin receptor (ETAR) , reverse primer

<400> 6
tcatcaggct ttaggactgg taac 24

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
ETB endothelin receptor (ETBR) , forward primer

<400> 7
tctctgtggc tctggctgtc 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
ETB endothelin receptor (ETBR) , reverse primer

<400> 8
tgctgaggtg aagggaagc 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
AT1 angiotensin receptor (AT1R) , forward primer

<400> 9
gctgaagact gtggccagtg 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
AT1 angiotensin receptor (AT1R) , reverse primer

<400> 10
atgcaggta ct~~t~~ggctac 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
1C adrenergic receptor (1cAR) , forward primer

<400> 11
tccacggtgc tgccc~~t~~tctc 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
1C adrenergic receptor (1cAR) , reverse primer

<400> 12
ttgatctggc agatggtctc 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
gp130 (cardiotrophin-1 receptor) , forward primer

<400> 13

cagaatgtgt atggagtcac 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
gp130 (cardiotrophin-1 receptor) , reverse primer

<400> 14
acccagactt caatgttgac 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
transforming growth factor (TGF) , forward primer

<400> 15
aactattgct tcagctccac 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
transforming growth factor (TGF) , reverse primer

<400> 16
acgttagtaca cgatggcag 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
protein kinase C (PKC) , forward primer

<400> 17

gcagccactg caccgacttc

20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

protein kinase C (PKC) , reverse primer

<400> 18

acgttagggat ctgacaagcc

20

<210> 19

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

c-myc , forward primer

<400> 19

acagcaaacc tccgcacag

19

<210> 20

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

c-myc , reverse primer

<400> 20

tggtcacgca gggcaaaaa

19

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
c-fos , forward primer

<400> 21
gccccatcgc agaccagagc

20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-fos , reverse primer

<400> 22
atgctgctga tgctcttgc

20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-ras , forward primer

<400> 23
caccatagag gtgagctctg

20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
c-ras , reverse primer

<400> 24
tcctcttggc ctgctgtgct

20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
-MHC , forward primer

<400> 25

cgcatggacc tggagcgagc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
-MHC , reverse primer

<400> 26

cgccgcatct tccggaactc

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
GAPDH , forward primer

<400> 27

accacagtcc atgccatcac

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
GAPDH , reverse primer

<400> 28

tccaccaccc tggcgctgta

20

<210> 29

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
forward primer (F1)

<400> 29

cgctcgagga agctgtgtga ccttggag

28

<210> 30

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
reverse primer (R2)

<400> 30

cgggatccct cttcctgaat ctggagcc

28

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:GFP-F

<400> 31

tgcgcaccat ggtgagcaag

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:GFP-R

<400> 32

ccttagcagaa gcacaggctg

20